Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]